Table 2.
FEV1 percentages and demographic features of the patients as to COPD stages and laboratory data
Stage I (n=9, 3.7%) |
Stage II (n=57, 23.5%) |
Stage III (n=117, 48.1%) |
Stage IV (n=60, 24.7%) |
P | |
Age (Year) | 64.78±12.48 | 65.32±13.89 | 70.93±10.35 | 66.97±10.17 | 0.007* |
Gender | 0.241** | ||||
Female | 3 (33.3%) | 22 (38.6%) | 42 (35.9%) | 16 (26.7%) | |
Male | 6 (66.7%) | 35 (61.4%) | 75 (64.1%) | 44 (73.3%) | |
Length (m) | 1.61±0.13 | 1.58±0.15 | 1.60±0.16 | 1.65±0.12 | 0.062* |
Kilo (kg) | 73.78±13.25 | 73.40±19.73 | 72.12±18.68 | 68.08±16.95 | 0.371* |
BMI(kg/m2) | 29.11±7.62 | 29.85±9.65 | 29.13±11.92 | 25.43±6.99 | 0.048* |
Levels of AAT | 193.89±45.95 | 199.44±59.29 | 211.01±63.16 | 212.22±51.26 | <0.001* |
Negatif | - | - | 1 (0.9%) | - | 0.097** |
Reference range | 3 (33.3%) | 22 (38.6%) | 31 (26.5%) | 14 (23.3%) | |
Positive | 6 (66.7%) | 35 (61.4%) | 85 (72.6%) | 46 (76.7%) | |
Exposure to tobacco | 0.660** | ||||
Yes | 6 (66.7%) | 27 (47.4%) | 58 (49.6%) | 34 (56.7%) | |
No | 3 (33.3%) | 30 (52.6%) | 59 (50.4%) | 26 (43.3%) | |
WBC | 7.89±1.42 | 10.47±4.88 | 10.38±5.15 | 10.69±4.11 | 0.245* |
CRP | 1.61±1.17 | 3.70±4.13 | 5.49±7.12 | 5.22±6.61 | 0.179* |
pH | 7.43±0.08 | 7.42±0.06 | 7.42±0.08 | 7.40±0.11 | 0.419* |
pCO2 | 41.22±8.39 | 41.06±9.47 | 43.25±11.48 | 47.54±12.29 | 0.056* |
pO2 | 46.67±12.12 | 49.56±14.77 | 46.09±11.39 | 43.10±13.44 | 0.194* |
Number of hospitalization in | 1±0.87 | 1.84±1.66 | 2.52±2.42 | 2 (0-15%) | 0.024* |
a year, median | |||||
Exitus in hospital | 0.049** | ||||
Yes | - | 1 (1.8%) | 3 (2.6%) | 5 (%) | |
No | 9 (100%) | 56 (98.2%) | 113 (97.4%) | 54 (91.5%) | |
Exitus in the first one year | 0.193** | ||||
Yes | 2 (22.2%) | 7 (12.3%) | 35 (23.7%) | 14 (23.7%) | |
No | 7 (77.8%) | 50 (87.7%) | 81 (69.8%) | 45 (76.3%) | |
Hospitalization to intensive | 0.008** | ||||
unit care in the first one year | |||||
Yes | - | 5 (8.8%) | 24 (20.7%) | 15 (25.0%) | |
No | 9 (100%) | 52 (91.2%) | 92 (79.3%) | 45 (75.0%) |
* Kruskall-Wallis test; **Ki-kare test